Abstract
Treatment-resistant depression (TRD) places a great burden not only to patients but society as a whole. A deep understanding of the neurobiological etiology of TRD will aid us to develop effective treatment strategies for TRD. In this chapter, we will discuss the recent findings on neurobiological mechanisms underlying TRD and corresponding novel pharmacological treatment strategies. Genetics and interactions with environmental factors; alterations in neural substrates, neuroinflammatory conditions, and glutamatergic neurotransmission; and glial cell pathology have been discussed. Anti-inflammatory drugs and ketamine have been suggested as novel treatment agents for TRD. Future studies that investigate the long-term efficacies and safety of such new treatment options in TRD are needed.
Original language | English |
---|---|
Title of host publication | Treatment Resistance in Psychiatry |
Subtitle of host publication | Risk Factors, Biology, and Management |
Publisher | Springer Singapore |
Pages | 99-107 |
Number of pages | 9 |
ISBN (Electronic) | 9789811043581 |
ISBN (Print) | 9789811043574 |
DOIs | |
Publication status | Published - 2018 Jan 1 |
Keywords
- Neurobiological etiology
- Novel pharmacological treatment option
- Treatment-resistant depression
ASJC Scopus subject areas
- Medicine(all)